MMP Inhibitors Based on Earlier Succinimide Strategies: From Early to New Approaches

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 519-547

  Santos, M Amélia ^a  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

Matrix metalloproteinases (MMPs, matrixins) promoting hydrolysis and peptide bond cleavage; MMP inhibitors based on earlier succinimide strategies early to new approaches; Peptidomimetic hydroxamate inhibitors

Indexed keywords

EID: 84889323514     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch24     Document Type: Chapter

References (95)

1. Woessner, J. F.; Nagase, H. Matrix Metalloproteinases and TIMPs. Oxford University Press: Oxford, 2000; pp 1-223.
2. Supuran, C. T.; Scozzafava, A. Matrix metalloproteinases (MMPs). In Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development, Smith, H.J.; Simons, C., Eds.; Taylors & Francis: London, New York, 2002; pp 35-61.
3. Nelson, A.R.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinases: clinical implications. J. Clin. Oncol. 2000, 18, 1135-1149.
4. Nagase, H.; Suzuki, K.; Itoh, Y.; Kan, C. C.; Gehring, M. R.; Huang, W.; Brew, K. Involvement of tissue inhibitors of metalloproteinases (TIMPs) during matrix metalloproteinase activation. Adv. Exp. Med. Biol. 1996, 389, 23-31.
5. Shapiro, S. H. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 1998, 10, 602-608.
6. Sternlicht, M.;Werb, Z. Howmatrix metalloproteinases regulate cell behaviour. Annu. Rev. Cell Dev. Biol. 2001, 17, 463-516.
7. Fingleton, B.; Matrix metalloproteinase as valid clinical targets. Curr. Pharm. Des. 2007, 13, 333-346.
8. Bigg, H. F.; Rowan, A. D. The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis. Curr. Opin. Pharmacol. 2001, 1, 314-320.
9. Ashley, R. A. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. Ann. NY Acad. Sci. 1999, 878, 335-346.
10. Rao, B. G. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharmaceut. Des. 2005, 11, 295-322.
11. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735-2776.
12. Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 1997, 97, 1359-1472.
13. Woessner, J. F., Jr. Matrix metalloproteinases inhibition. From the Jurassic to the third millennium. Ann. NY. Acad. Sci. 1999, 878, 388-403.
14. Chambers, A. F.; Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Nac. Cancer Inst. 1997, 89, 1260-1270.
15. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295, 2387-2392.
16. Skiles, J.W.; Gonnella, N. C.; Jeng, A. The design, structure and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem. 2004, 11, 2911-2977.
17. Breuer, E.; Frant, J.; Reich, R. Recent non-hydroxamate matrix metalloproteinase inhibitor. Exp. Opin. Ther. Pat. 2005, 15, 253-269.
18. Overall, C. M.; Lopez-Otin, C. Strategies forMMPinhibition in cancer innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-652.
19. Mannello, F.; Tonti, G.; Papa, S. Matrix metalloproteinase inhibitors as targets of anticancer therapeutics. Curr. Cancer Drug Targets 2005, 5, 285-298.
20. Matter, H.; Schudok, M. Recent advances in the design of matrix metalloproteinase inhibitors. Curr. Opin. Drug Discov. Devel. 2004, 7, 513-535.
21. Jacobsen, F. E.; Lewis, J. A.; Cohen, S. M. The design of inhibitors for medicinally relevant metalloproteins. Chem. Med. Chem. 2007, 2, 152-171.
22. Nuti, E.; Tuccinardi, T.; Rossello, A. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des. 2007, 13, 2087-2100.
23. Wada, C. K. The evolution of matrix metalloproteinase inhibitors. drug discovery program at Abbott laboratories. Curr. Top. Med. Chem. 2004, 4, 1255-1267.
24. Fisher, J. F.; Mobashery, S. Recent advances inMMPinhibitor design. Cancer Metast. Rev. 2006, 25, 115-136.
25. Pirard, B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov. Today 2007, 12, 640-646.
26. Visse, R.; Nagase, H. Matrix metallopronases and tissue inhibitor of metalloproteases:structure, function and biochemistry. Ciac. Res. 2003, 92, 827-839.
27. Supuran, C. T.; Casini, A.; Scozzafava, A. Protease inhibitors of sulphonamide type:anticancer, antiinflammatory and antiviral agents. Med. Res. Rev. 2003, 23, 535-558. 1-33.
28. Borkakoti, N. Matrix metalloproteases: variations on a theme. Progr. Biophys. Mol. Biol. 1998, 70, 73-94.
29. Terp, G. E.; Cruciani, G.; Christensen, I. T.; Jorgensen, F. S. Structural differences of matrix metalloproteinases-by the GRID/CPCA approach. J. Med. Chem. 2002, 45, 2675-2684.
30. Pirard, B.; Matter, H. Matrix metalloproteinase target family landscape: a chemomatrix approach to ligand selectivity based on protein binding site analysis. J. Med. Chem. 2006, 49, 51-69.
31. Dorman, G.; Kocsis-Sommer, K.; Spadonic, C.; Peter, F. MMP inhibitors in cardiac diseases: an update. Recent Pat. Cardiovasc. Drug Discov. 2007, 2, 186-194.
32. Brown, S.; Meroueh, S. O.; Fridman, R.; Mobashery, S. Quest for selectivity in inhibition of matrix metalloproteinase inhibitors. Curr. Top. Med. Chem. 2004, 4, 1227-1238.
33. Morales, R.; Perrier, S.; Florent, J.-M.; Beltra, J.; Dufour, S.; De Mendez, I.; Manceau, P.;Tertre, A.; Moreau, F.; Compere, D.; Dublanchet, A.-C.; O'Gara, M. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J. Mol. Biol. 2004, 341, 1063-1076.
34. Broadhurst, M. J.; Johnson, W. H.; Lawton, G.; Handa, B. K.; Machin, P. J. Phosphinic acid derivative. European Patent EPO276436, 1998.
35. Brown, P. D. Clinical trials of a low molecular weight matrix metalloproteinase inhibitor in cancer. Ann NY. Acad. Sci. 1994, 732, 217-221;
36. Darlak, K.; Miller, R. B.; Stack, M. S.; Spatola, A. F.; Gray, R.D. Thiol-based inhibitors of mammalian collagenase. Substituted amide and peptide derivatives of the leucine analogue, 2-[R,S)-mercaptomethyl]-4-methylpentanoic acid. J. Biol. Chem. 1990, 265, 5199-5205.
37. Markwell, R. E.; Hunter, D. J.; Ward, R. W. Peptides with collagenase inhibiting activity. European Patent EP0320118, 1989.
38. Markwell, R. E.; Hunter, D. J.;Ward, R.W. Peptides with collagenase inhibiting activity. World Patent WO9309136, 1989.
39. Odake, S.; Morita, Y.; Morikawa, T.;Yoshida, N.; Hori, H.; Nagai, Y. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids. Biochem. Biophys. Res. Comm. 1994, 199, 1442-1446.
40. Matter, H.; Schudok, M. Recent advances in the design of matrix metalloproteinase inhibitors. Curr. Opin. Drug Discov. Devel. 2004, 7, 513-535.
41. Wu, J.; Rush, T. S., III; Hotchandani, R.; Du, X.; Geck, M.; Collins, E.; Xu, Z.-B.; Skotnicki, J.; Levin, J. I.; Lovering, F. E. Identification of potent and selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 4105-4109.
42. Bernardo, M. M.; Brown, S.; Li, Z. H.; Fridman, R.; Mobashery, S. Design, synthesis and characterization of potent. Slow-binding inhibitors that are selective for gelatinases. J. Biol. Chem. 2002, 277, 11201-11207.
43. Matziari, M.; Beau, F.; Cuniasse, P.; Dive, V.; Yiotakis, A. Evaluation of P10-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. J. Med. Chem. 2004, 47, 325-336.
44. Puerta, D. T.; Mongan, J.; Tran, B. L.; Mc Cammon, J. A.; Cohen, S. M. Potent, selective pyrone-based inhibitors of stromelysin-1. J. Amer. Chem. Soc. 2005, 127, 14148-14149.
45. Blagg, J. A.; Noe, M. C.; Wolf-Gouveia, L. A.; Reiter, L. A.; Laird, E. R.; Chang, S. P. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg. Med. Chem. Lett. 2005, 15, 1807-1810.
46. Esteves, M. A.; Cachudo, A.; Ribeiro, C.; Chaves, S.; Santos, M. A., New hydroxypyrimidinone chelators as potential matrix metalloproteinase inhibitors. In Metal Ions in Biology and Medicine, Alpoim M. C.; Morais P. V.; Santos, M. A.; Cristovaó, A. J.; Centeno, J.; Collery, Ph., Eds; John Libbey Eurotext: Paris, 2006; Vol. 9, pp 35-39.
47. Castelhano, A. L.; Billedeau, R.; Dewdney, N.; Donnelly, S.; Horne, S.; Kurz, L. J.; Liak, T. J.; Martin, R.; Uppington, R.; Yuan, Z.; Krantz, A. Novel indolactam-based inhibitors of matrix metalloproteinases. Bioorg. Med. Chem. Lett. 1995, 5, 1415-1420.
48. Johnson, W. H.; Roberts, N. A.; Borkakoti, N. Collagenase inhibitors: their design and potential therapeutic use. J. Enzyme Inhib. 1987, 2, 1-22.
49. Rothenberg, M. L.; Nelson, A. R.; Hande, K. R. New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells 1999, 1, 237-240.
50. Hutchinson, J.W.; Tierney, G. M.; Parsons, S. L.; Davis, T. R. C. Dupuytren's disease and frosen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J. Bone Joint Surg. Br. 1998, 80-B, 907-908.
51. Rasmussen, H. S.; McCann, P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on Batimastat and Marimastat. Pharmacol. Ther. 1997, 75, 69-75.
52. Hoekstra, R.; Skens, F. A. L. M.; Verwej, J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 2001, 6, 415-427.
53. Rothemberg, M. L.; Nelson, A. R.; Hande, K. N. New drugs on the horizon: matrix metalloproteinase inhibitors. Oncologist 1998, 3, 271-274.
54. Folgueras, A. R.; Pendas, A. M.; Sanchez, L. M.; Lopez-Otin, C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 2004, 48, 411-424.
55. Dahlberg, L.; Billinghhurs, R. C.; Manner, P.; Nelson, S.; Webb, G.; Ionescu, M.; Reiner, A.; Tanzer, M.; Zukor, D.; Chen, J.; Van Wart, H. E.; Poole, A. R. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum. 2000, 43, 673-682.
56. Scatena, R. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. a novel pharmaceutical approach for tissue remodelling-related diseases. Exp. Opin. Invest. Drugs 2000, 9, 2159.
57. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Teschesche, H.; Bode, W. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry 1995, 34, 14012-14120.
58. Xue, C.-B.; He, X.; Roderick, J.; DeGrado, W. F.; Cherney, R. J.; Hardman, K. D.; Nelson, D. J.; Copeland, R.; Jafee, A.; Decicco, B. D.; Design, C. P. Synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-a production. J. Med. Chem. 1998, 41, 1745-1748.
59. Steinman, D. H.; Curtin, M. L.; Garland, R. B.; Davidsen, S. K.; Heyman, H. R.; Holms, J. H.; Albert, D. H.; Magoc, T. J.; Nagy, I. B.; Marcotte, P. A.; Li, J.; Morgan, D. W.; Hutchins, C.; Summers, J. B. The design synthesis and structure-activity relationships of a series of macrocyclicMMP inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2087-2092.
60. Xue, C.-B.;Voss, M. E.; Nelson, D. J.; Duan, J. J.-W.; Cherney, R. J.; Jacobson, I. C.; He, X.; Roderick, J.; Chen, L.; Corbett, R. L.;Wang, L.; Meyer, D.T.;Kennedy, K.; DeGrado, W. F.; Hardman, K. D.; Teleha, C. A.; Jaffee, B. D.; Liu, R.-Q.; Copeland, R. A.; Covington, M. B.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Magolda, R. L.;Wexler, R. R.; Decicco, C. P. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor release in vitro and in vivo. J. Med. Chem. 2001, 44, 2636-2660.
61. Campion, C.; Davidson, A. H.; Dickens, J. P.; Crimmin, M. J. PCT Patent Application WO9005719, 1990; Chem. Abstr. 1990, 113, 212677.
62. Crimmin, M. J.; Beckett, P. R.; Davis, M. H. PCT Patent Application WO9421625, 1994; Chem. Abstr. 1995, 122, 188173.
63. Crimmin, M. J.; Ayscough, A. P.; Beckett, R. P. PCT Patent Application WO9424140, 1994; Chem. Abstr. 1995, 123, 144644.
64. Kottirsch, G.; Koch, G.; Feifel, R.; Neumann, U. b-Aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J. Med. Chem. 45, 2002, 2289-2293.
65. Koch, G.;Kottirsch, G.;Wietfeld, B.; Kuster, E. Process development of a dualMMP/TNF inhibitor (SDZ 242-484). Org. Process Res. Dev. 6, 2002, 652-659.
66. Di Martino, M.; Wolff, C.; High, W.; Stoup, G.; Hoffman, S.; Laydon, J.; Lee, J. C.; Bertolini, D.; Galloway, W. A.; Crimmin, M. J.; Davis, M.; Davies, S. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF-a processing. Inflamm. Res. 46, 1997, 211-215.
67. Clements, J. M.; Cossins, J. A.;Wells, G. M. A.; Corkill, D. J.; Helfrich, K.;Wood, L. M.; Pigott, R.; Stabler, G.; Ward, G.A.; Gearing, A. J. H.; Miller, K. M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-a inhibitor. J. Neuroimmunol. 74, 1997, 85-94.
68. Janser, P.; Neumann, U.; Miltz, W.; Feifel, R.; Buhl, T. A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg. Med. Chem. Lett. 16, 2006, 2632-2636.
69. Marcq,V.; Mirand, C.; Decarme, M.; Emonard, H.; Hornebeck,W.MMPs inhibitors: new succinyl hydroxamates with selective inhibition of MMP-2 over MMP-3. Bioorg. Med. Chem. 13, 2003, 2843-2846.
70. Hirayama, R.;Yamamoto, M.; Tsukida, T.; Matsuo, K.; Obata, Y.; Sakamoto, F.; Ikeda, S. Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors. Bioorg. Med. Chem. 5, 1997, 765-778.
71. Fray, M. J.; Dickinson, R. P. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorg. Med. Chem. Lett. 11, 2001, 571-574.
72. Fray, M. J.; Burslem, M. F.; Dickinson, R. P. Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P30 group chirality. Bioorg. Med. Chem. Lett. 11, 2001, 567-570.
73. Chen, J. J.; Zhang, Y.; Hammond, S.; Dewdney, N.; Ho, T.; Lin, X.; Browner, M. F.; Castelhano, A. L. Bioorg. Med. Chem. Lett. 1996, 6, 1601.
74. Sheppard, G. S.; Florjancic, A. S.; Giesler, J. R.; Xu, L.; Guo, Y.; Davidsen, S. K.; Marcotte, P. A.; Elmore, I.; Albert, D. H.; Magoc, T. J.; Bouska, J. J.; Goodfellow, C. L.; Morgan, D. W.; Summers, J. B. Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 3251-3256.
75. Sheppard, G. S.; Pireh, D.; Carrera, G. M., Jr.; Bures, M. G.; Heyman, H. R.; Steinman, D. H.; Davidsen, S. K.; Phillips, J. G.; Guinn, D. E.; May, P. D.; Conway, R. G.; Rhein, D. A.; Calhoun, W. C.; Albert, D. H.; Magoc, T. J.; Carter, G.W.; Summers, J. B., Jr. 3-(2-3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists. J. Med. Chem. 1994, 37, 2011-2032.
76. Campestre, C.; Tortorella, P.; Agamennone, M.; Preziuso, S.; Biasone, A.; Nuti, E.; Rossello, A.; Gallina, C. Peptidy 3-substituted 1-hydroxyureas as isosteric analogues of succinyl hydroxamate MMP inhibitors. Eur. J. Med. Chem. 2008, 43, 1008-1014.
77. Von Roedern, E. G.; Brandstetter, H.; Engh, R. A.; Bode, W.; Grams, F.; Moroder, L. Bissubstituted malonic acid hydroxamate derivatives as inhibitors of human neutrophil collagenase (MMP8). J. Med. Chem. 1998, 41, 3041-3047.
78. Grams, F.; Reinemer, P.; Powers, J.C.; Kleine, T.; Pieper, M.; Tschesche, H.; Huber, R.; Bode, W. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Eur. J. Biochem. 1995, 228, 830-841.
79. Von Roedern, E. G.; Grams, F.; Brandstetter, H.; Moroder, L. Design and synthesis of malonic acid-based inhibitors of human neutrophil collagenase (MMP8). J. Med. Chem. 1998, 41, 339-345.
80. Brandstetter, H.; Engh, R. A.; Von Roedern, E. G.; Moroder, L.; Huber, R.; Bode, W.; Grams, F. Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. a new binding mode explains apparently anomalous data. Protein Sci. 1998, 7, 1303-1309.
81. Fisher, J. F.; Mobashery, S. Recent advances in MMP inhibitor Design. Cancer Metastasis Rev. 2006, 25, 115-136.
82. Bottomley, K. M.; Johnson, W. H.; Walter, D. S. Matrix metalloproteinase inhibitors in arthritis. J. Enzyme Inhib. 1998, 13, 79-192.
83. Lewis, E. J.; Bishop, J.; Bottomley, K. M. K.; Bradshaw, D.; Brewster, M.; Broadhurst, M. J.; Brown, P. A.; Budd, J. M.; Elliott, L.; Greenham, A. K.; Johnson, W. H.; Nixon, J. S.; Rose, F.; Sutton, B.;Wilson, K. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br. J. Pharmacol. 1997, 121, 540-546.
84. Broadhurst, M. J.; Johnson, W. H.; Walter, D. S. GB Patent Application GB 2326881A, 1999; Chem. Abstr. 1999, 130, 110060.
85. Santos, M. A.; Marques, S. M.; Gil, M.; Tegoni, M.; Chaves, S. New metalloenzyme inhibitors with potential clinic application. PT Patente 103003; 2003.
86. Santos, M. A. Iminodiacetyl-monohydroxamate derivatives as potent and selective MMP inhibitors. In MetalIons in Biologyand Medicine, Alpoim, M. C.;Morais,P.V.; SantosM.A., Cristovaó A. J., Centeno J., Collery Ph., Eds; John Libbey Eurotext: Paris, 2006; Vol. 9, pp 117-121.
87. Marques, S. M.; Rossello, A.; Santos, M. A. Metalloenzyme inhibitors with potential medical application: 1-hydroxy-piperazine-2,6-dione as a new zinc binding group. PT Patente 103897, 2007.
88. Bode, W.; Fernandez-Catalan, C.; Grams, F.; Gomis-Rüth, F.-X.; Nagase, H.; Tschesche, H.; Maskos, K. Insights into MMP-TIMP interactions. Ann. NY Acad. Sci. 1999, 878, 73-91.
89. Kontogiorgis, C. A.; Papaioannou, P.; Hadjipavlou-Litina, D. J. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Curr. Med. Chem. 2005, 12, 339-355.
90. Santos, M. A.; Marques, S. M.; Tuccinardi, T.; Carelli, P.; Panelli, L.; Rossello, A. Design, synthesis and molecular modelling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors. Bioorg. Med. Chem. 2006, 14, 7539-7550.
91. Hanessian, S.; Moitessier, N. Structure-based design, synthesis, and hemopsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. Curr. Top. Med. Chem. 2004, 4, 1269-1287.
92. Overall, C. M.; Kleifeld, O. Validating matrix metalloproteinases as drug targets and antitargets for cancer therapy. Nat. Rev. Cancer 2006, 6, 227-239.
93. Marques, S. M.; Nuti, E.; Rossello, A.; Supuran, C. T.; Tuccinardi, T.; Adriano Martinelli, A.; and Santos, M. A. Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate Benzenesulfonamide Conjugates. J. Med. Chem. 2008, 51, 7968-7979.
94. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.;Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a non-peptidic, potent and orally active stromelysin that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525.
95. Reiter, L. A.; Robinson, R. P.; McClure, K. F.; Jones, C. S.; Reese, M. R.; Mitchell, P. G.; Otterness, I. G.; Bliven, M. L.; Liras, J.; Cortina, S. R.; Donahue, K. M.; Eskra, J. D.; Griffiths, R. J.; Lame, M. E.; Lopez-Anaya, A.; Martinelli, G. J.; McGahee, S. M.; Yocum, S. A.; Lopresti-Morrow L. L.; Tobiassen L. M.; Vaughn-Bowser, M. L. Pyrancontaining sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2004, 14, 3389-3395.